PMID- 15188947
OWN - NLM
STAT- MEDLINE
DCOM- 20041014
LR  - 20200225
IS  - 0160-9289 (Print)
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Linking)
VI  - 27
IP  - 5
DP  - 2004 May
TI  - Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac 
      transplantation: a randomized, placebo-controlled study.
PG  - 295-9
AB  - BACKGROUND: The number of patients awaiting heart transplantation is increasing 
      in proportion to the waiting period for a donor. Studies have shown that coenzyme 
      Q10 (CoQ10) has a beneficial effect on patients with heart failure. HYPOTHESIS: 
      The purpose of the present double-blind, placebo-controlled, randomized study was 
      to assess the effect of CoQ10 on patients with end-stage heart failure and to 
      determine if CoQ10 can improve the pharmacological bridge to heart 
      transplantation. METHODS: A prospective double-blind design was used. Thirty-two 
      patients with end-stage heart failure awaiting heart transplantation were 
      randomly allocated to receive either 60 mg U/day of Ultrasome--CoQ10 (special 
      preparation to increase intestinal absorption) or placebo for 3 months. All 
      patients continued their regular medication regimen. Assessments included 
      anamnesis with an extended questionnaire based partially on the Minnesota Living 
      with Heart Failure Questionnaire, 6-min walk test, blood tests for atrial 
      natriuretic factor (ANF) and tumor necrosis factor (TNF), and echocardiography. 
      RESULTS: Twenty-seven patients completed the study. The study group showed 
      significant improvement in the 6-min walk test and a decrease in dyspnea, New 
      York Heart Association (NYHA) classification, nocturia, and fatigue. No 
      significant changes were noted after 3 months of treatment in echocardiography 
      parameters (dimensions and contractility of cardiac chambers) or ANF and TNF 
      blood levels. CONCLUSIONS: The administration of CoQ10 to heart transplant 
      candidates led to a significant improvement in functional status, clinical 
      symptoms, and quality of life. However, there were no objective changes in echo 
      measurements or ANF and TNF blood levels. Coenzyme Q10 may serve as an optional 
      addition to the pharmacologic armamentarium of patients with end-stage heart 
      failure. The apparent discrepancy between significant clinical improvement and 
      unchanged cardiac status requires further investigation.
FAU - Berman, Marius
AU  - Berman M
AD  - Department of Cardiothoracic Surgery, Heart-Lung Transplant Unit, Rabin Medical 
      Center, Beilinson Campus, Potah Tikva, Israel. mariusby@yahoo.com
FAU - Erman, Arie
AU  - Erman A
FAU - Ben-Gal, Tuvia
AU  - Ben-Gal T
FAU - Dvir, Dan
AU  - Dvir D
FAU - Georghiou, Georgios P
AU  - Georghiou GP
FAU - Stamler, Alon
AU  - Stamler A
FAU - Vered, Yaffa
AU  - Vered Y
FAU - Vidne, Bernardo A
AU  - Vidne BA
FAU - Aravot, Dan
AU  - Aravot D
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Coenzymes)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 1339-63-5 (Ubiquinone)
RN  - 85637-73-6 (Atrial Natriuretic Factor)
RN  - EJ27X76M46 (coenzyme Q10)
SB  - IM
CIN - Clin Cardiol. 2004 Oct;27(10):A26; author reply A26, A30. PMID: 15553298
MH  - Adult
MH  - Aged
MH  - Atrial Natriuretic Factor/blood
MH  - Cardiotonic Agents/*therapeutic use
MH  - Coenzymes
MH  - Double-Blind Method
MH  - Exercise Tolerance
MH  - Female
MH  - Heart Failure/blood/diagnostic imaging/*drug therapy
MH  - Heart Transplantation
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Quality of Life
MH  - Recovery of Function
MH  - Severity of Illness Index
MH  - Tumor Necrosis Factor-alpha/metabolism
MH  - Ubiquinone/*analogs & derivatives/*therapeutic use
MH  - Ultrasonography
MH  - Waiting Lists
PMC - PMC6654743
EDAT- 2004/06/11 05:00
MHDA- 2004/10/16 09:00
PMCR- 2006/12/05
CRDT- 2004/06/11 05:00
PHST- 2004/06/11 05:00 [pubmed]
PHST- 2004/10/16 09:00 [medline]
PHST- 2004/06/11 05:00 [entrez]
PHST- 2006/12/05 00:00 [pmc-release]
AID - CLC4960270512 [pii]
AID - 10.1002/clc.4960270512 [doi]
PST - ppublish
SO  - Clin Cardiol. 2004 May;27(5):295-9. doi: 10.1002/clc.4960270512.